Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

被引：20

作者：

Petrich, Adam ^{[1
]}

Kahl, Brad ^{[1
]}

Bailey, Howard ^{[1
]}

Kim, Kyungmann ^{[2
]}

Turman, Nancy ^{[1
]}

Juckett, Mark ^{[1
]}

机构：

[1] Univ Wisconsin, Ctr Comprehens Canc, Dept Med, Madison, WI USA

[2] Univ Wisconsin, Ctr Comprehens Canc, Dept Biostat & Med Informat, Madison, WI USA

来源：

LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 01期

关键词：

doxercalciferol; myelodysplastic syndrome; phase II study;

D O I：

10.1080/10428190701713648

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We conducted a phase II trial of doxercalciferol, a vitamin D2 analogue, in 15 patients with MDS. Each received doxercalciferol 12.5g orally daily for 12 weeks. Nine of 15 patients completed the prescribed course and of these, six had stable disease. No patient had a response (IWG criteria) and overall eight patients experienced progressive disease while on therapy. Two patients with chronic myelomonocytic leukemia (CMML) had a marked rise in monocytes on study. Overall the treatment was well tolerated. One patient was removed from study due to hypercalcemia. We conclude that short-term treatment with doxercalciferol has limited activity in patients with MDS.

引用

页码：57 / 61

页数：5

共 15 条

[11] THE EFFECT OF 1-HYDROXYVITAMIN D3 FOR PROLONGATION OF LEUKEMIC TRANSFORMATION-FREE SURVIVAL IN MYELODYSPLASTIC SYNDROMES [J].

MOTOMURA, S ;

KANAMORI, H ;

MARUTA, A ;

KODAMA, F ;

OHKUBO, T .

AMERICAN JOURNAL OF HEMATOLOGY, 1991, 38 (01) :67-68

[12] Novel ring A stereoisomers of 2-methyl-1α,25-dihydroxyvitamin D3 and 2-methyl-20-epi-1α,25-dihydroxyvitamin D3:: Transactivation of target genes and modulation of differentiation in human promyelocytic leukemia (HL-60) cells [J].

Nakagawa, K ;

Kurobe, M ;

Ozono, K ;

Konno, K ;

Fujishima, T ;

Takayama, H ;

Okano, T .

BIOCHEMICAL PHARMACOLOGY, 2000, 59 (06) :691-702

[13]

Ripple GH, 1999, SEMIN ONCOL, V26, P217

[14] OPTIMAL 2-STAGE DESIGNS FOR PHASE-II CLINICAL-TRIALS [J].

SIMON, R .

CONTROLLED CLINICAL TRIALS, 1989, 10 (01) :1-10

[15] TREATMENT OF ACUTE MYELOID-LEUKEMIA IN THE ELDERLY WITH LOW-DOSE CYTARABINE, HYDROXYUREA, AND CALCITRIOL [J].

SLAPAK, CA ;

DESFORGES, JF ;

FOGAREN, T ;

MILLER, KB .

AMERICAN JOURNAL OF HEMATOLOGY, 1992, 41 (03) :178-183

← 1 2 →